氨酸激酶促进慢性交感激活诱导的心脏重塑
Wenqi Li1, Yuzhong Zhu1, Wenjing Wang2
1Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Bioscience reports
|August 31, 2023
概括
Src氨酸激酶在过度激活β-上腺素受体 (β-AR) 中起着关键作用,驱动心脏重塑. 向Src可能为心血管疾病提供新的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 心脏重塑是心血管疾病发病的核心.
- 过度的β-上腺素受体 (β-AR) 激活是已知的心脏重塑的驱动因素.
- 由于β-AR诱导心脏重塑的精确分子机制尚未完全理解.
研究的目的:
- 为了确定β-AR诱导的心脏重塑中的关键分子参与者.
- 阐明Src氨酸激酶在这个过程中的作用.
- 调查针对Src.的治疗潜力.
主要方法:
- 使用异二醇 (ISO) 诱导心脏重塑的体内研究.
- 在心脏纤维细胞和心肌细胞的体外实验.
- 对β-AR/Src/ERK信号通路的分析.
主要成果:
- 鉴定出Src氨酸激酶是ISO诱导的心脏缩,纤维化和体内炎症的调解者.
- Src在体外促进了心脏纤维细胞的β-AR介导的增殖和转基因分化以及心肌细胞的缩.
- Src通过β-AR调节细胞外信号调节蛋白激酶 (ERK1/2) 途径的激活.
结论:
- Src氨酸激酶显著促进β-AR诱导的心脏重塑.
- β-AR/Src/ERK信号通路对于心脏纤维细胞的心脏重塑至关重要.
- Src代表了缓解心脏重塑的潜在治疗目标.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Receptor Tyrosine Kinases
13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16


